Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALA-CORT vs AMCINONIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing prostaglandin and leukotriene synthesis, and exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.
Corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress inflammatory cell migration and cytokine production.
Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (FDA),Off-label: Atopic dermatitis, psoriasis, contact dermatitis, lichen planus, discoid lupus erythematosus
Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (e.g., psoriasis, eczema, contact dermatitis)
Topical: Apply a thin film to affected area 3-4 times daily. Dosage strength: 0.5% cream or ointment.
Topical: Apply a thin film to affected skin areas twice daily. Maximum 60 g per week. Use for no longer than 2 consecutive weeks.
Terminal elimination half-life: 1–2 hours for hydrocortisone (active component), prolonged in liver disease or with concurrent CYP3A4 inhibitors.
Terminal elimination half-life is approximately 2–4 hours, but following topical application, systemic half-life may be prolonged due to continuous absorption from the skin.
Topically applied; systemic absorption is minimal but can be increased with use on large areas, occlusive dressings, or damaged skin. Absorbed portion is metabolized primarily in the liver via hepatic microsomal enzymes (CYP3A4) and excreted by the kidneys.
Primarily hepatic metabolism via CYP3A4; metabolites are excreted renally.
Primarily hepatic metabolism (approximately 95%) followed by renal excretion of inactive metabolites (<5% unchanged). Biliary/fecal excretion is negligible.
Primarily renal; <5% fecal. About 40% of a dose is excreted in urine as unchanged drug and glucuronide conjugates.
Hydrocortisone is approximately 90–95% bound to corticosteroid-binding globulin (CBG, transcortin) and albumin.
Approximately 95–99% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin.
Apparent volume of distribution (Vd) is approximately 0.4–0.6 L/kg, indicating moderate tissue distribution and limited penetration into CNS.
Apparent volume of distribution is about 0.14–0.3 L/kg, indicating extensive tissue distribution.
Topical: Bioavailability is negligible (<1%) through intact skin; may increase (up to 30%) with damaged skin or occlusive dressings. Rectal: Bioavailability is approximately 10–20% via mucosal absorption, with first-pass metabolism reducing systemic exposure.
Topical: Bioavailability is high but variable due to skin barrier; systemic absorption ranges from 0.5% to 2% with intact skin, higher with occlusion or inflamed skin. Intralesional: Complete systemic absorption.
No adjustment required for topical use; systemic absorption minimal.
No adjustment required for topical use. Systemic absorption is minimal.
No adjustment required for topical use; hepatic metabolism negligible.
No adjustment required for topical use. Systemic absorption is minimal.
Children ≥2 years: Apply a thin film to affected area 2-3 times daily. Use lowest potency preparation; avoid prolonged use.
Use lowest effective dose for shortest duration. Apply sparingly to small areas. Avoid use in children <2 years of age. For children ≥2 years: apply thin film once or twice daily. Limit treatment to 5-7 days.
Use lowest effective dose; monitor for skin atrophy and systemic effects due to thinner skin and increased percutaneous absorption.
Use lowest effective dose for shortest duration. Apply sparingly due to thinner skin and increased systemic absorption risk. Avoid use on large areas or under occlusive dressings.
None
None.
Systemic absorption may cause reversible HPA axis suppression,Cushing's syndrome, hyperglycemia, and glucosuria with prolonged use,Local adverse reactions: atrophy, striae, telangiectasias, acneiform eruptions, perioral dermatitis,May mask signs of infection,Use with caution in pediatric patients due to increased susceptibility to HPA axis suppression,Avoid use on face, intertriginous areas, and under occlusive dressings unless directed by physician
Systemic absorption with prolonged use or large areas may cause HPA axis suppression, Cushing's syndrome, or hyperglycemia.,Local adverse reactions include skin atrophy, striae, telangiectasias, and secondary infections.,Avoid use on face, axillae, or groin unless directed; use caution in patients with impaired skin integrity.,Not recommended for diaper dermatitis or for use under occlusive dressings.
Hypersensitivity to any component of the formulation,Untreated bacterial, viral, fungal, or parasitic skin infections,Viral skin infections (e.g., herpes simplex, varicella) at treatment site,Perioral dermatitis,Rosacea
Hypersensitivity to amcinonide or any component of the formulation.,Untreated bacterial, viral, or fungal infections at the application site.,Topical application for ophthalmic or intravaginal use.
No known food interactions with topical ALA-CORT.
No known food interactions. Avoid excessive ingestion of corticosteroids systemically, but topical application does not require dietary restrictions.
FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies show increased risk of cleft palate. Second/third trimester: Risk of intrauterine growth restriction, adrenal suppression in fetus. Avoid prolonged use.
Pregnancy Category C. Topical corticosteroids, including amcinonide, have not been adequately studied in pregnant women. Animal studies have shown teratogenic effects with systemic administration, but the risk with topical application is low due to minimal systemic absorption. However, prolonged or large-area use may increase systemic absorption and potential fetal risk. First trimester: Avoid unless clearly needed. Second and third trimesters: Use with caution, avoiding extensive areas, prolonged use, or occlusive dressings.
Provides small amounts in breast milk; M/P ratio unknown. At maternal doses up to 80 mg/day, no adverse effects reported in infants. Consider risk-benefit with high doses or prolonged therapy.
No data available on excretion into breast milk. Systemic absorption after topical application is minimal but may occur with prolonged or large-area use. Caution should be exercised as a risk to the infant cannot be excluded. Use only if clearly needed and apply to smallest area for shortest duration. M/P ratio: Not established.
Pregnancy-induced pharmacokinetic changes (increased clearance, volume of distribution) may require increased dosing, but clinical response should guide adjustment. Avoid high doses and prolonged use.
No disease-specific pharmacokinetic changes for amcinonide. Dosing adjustments are not generally recommended, but consider using the lowest effective dose, smallest area, and shortest duration to minimize systemic absorption. Avoid occlusive dressings and use on large areas or broken skin due to increased absorption.
ALA-CORT (hydrocortisone acetate 2.5% and pramoxine HCl 1%) is a topical corticosteroid with anesthetic. Use for short-term relief of pruritus and inflammation in corticosteroid-responsive dermatoses. Avoid prolonged use on intertriginous or occluded areas. Limit to <2 weeks continuous use in adults to avoid skin atrophy. Not recommended for children <2 years.
Amcinonide is a high-potency topical corticosteroid, typically used for short-term treatment of corticosteroid-responsive dermatoses. Due to its potency, it should be applied sparingly and not used under occlusion unless directed. Avoid use on face, groin, or axillae due to increased risk of skin atrophy and systemic absorption. Monitor for local adverse effects such as striae, hypopigmentation, or rosacea-like dermatitis. Systemic absorption can occur with extensive use, particularly in children or when applied to large body surface areas.
Apply a thin layer to affected area no more than 3-4 times daily.,Do not cover with bandages or plastic unless directed by doctor.,Avoid contact with eyes, mouth, or broken skin.,Discontinue and notify doctor if infection, irritation, or no improvement after 7 days.,Do not use for diaper dermatitis or under diapers/occlusive dressings.,Keep out of reach of children.
Apply a thin layer to affected skin only; do not use on broken or infected skin unless prescribed.,Wash hands after application unless treating hands.,Do not cover treated area with bandages or plastic wrap unless instructed by your doctor.,Avoid contact with eyes, mouth, and mucous membranes.,Do not use for longer than prescribed; overuse can lead to skin thinning and other side effects.,Inform your doctor if you are pregnant, breastfeeding, or planning to become pregnant.
No interactions on record
"Magnesium trisilicate, an antacid, can significantly reduce the oral bioavailability of Amcinonide, a topical corticosteroid, when administered concurrently. The mechanism involves magnesium ions chelating with the corticosteroid or altering gastrointestinal pH, thereby impairing dissolution and absorption of Amcinonide. This interaction may lead to reduced efficacy of Amcinonide therapy, particularly when higher systemic exposure is required for therapeutic effect."
"Concurrent use of topical corticosteroids like Amcinonide and systemic acetylcholinesterase inhibitors such as Pyridostigmine may potentiate adverse effects, particularly electrolyte disturbances and cardiovascular events. Pyridostigmine enhances cholinergic activity, which can lead to increased gastrointestinal motility and bronchial secretions, while Amcinonide's mineralocorticoid activity can cause sodium and water retention, aggravating fluid overload and hypertension. This interaction is clinically significant in patients with myasthenia gravis receiving Pyridostigmine, as corticosteroid-induced hypokalemia may worsen muscle weakness."
"The combination of leflunomide, an immunomodulator that inhibits dihydroorotate dehydrogenase and suppresses lymphocyte proliferation, with amcinonide, a potent topical corticosteroid, may result in additive immunosuppression, increasing the risk of serious infections, including bacterial, viral, fungal, and opportunistic infections. Systemic absorption of topical corticosteroids can occur, especially with prolonged use on large areas, damaged skin, or under occlusive dressings, potentiating adrenal suppression and other systemic corticosteroid effects. Patients receiving both agents require careful monitoring for signs of infection, adrenal insufficiency, and other adverse effects related to enhanced immunosuppression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALA-CORT vs AMCINONIDE, answered by our medical review team.
ALA-CORT is a Topical Corticosteroid that works by Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing prostaglandin and leukotriene synthesis, and exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.. AMCINONIDE is a Topical Corticosteroid that works by Corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress inflammatory cell migration and cytokine production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALA-CORT and AMCINONIDE depend on the specific clinical indication. These are both Topical Corticosteroid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALA-CORT is: Topical: Apply a thin film to affected area 3-4 times daily. Dosage strength: 0.5% cream or ointment.. The standard adult dose of AMCINONIDE is: Topical: Apply a thin film to affected skin areas twice daily. Maximum 60 g per week. Use for no longer than 2 consecutive weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALA-CORT and AMCINONIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALA-CORT is classified as Category C. FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies show increased risk of cleft palate. Second/third trimester: Risk of intrauterine growth restri. AMCINONIDE is classified as Category C. Pregnancy Category C. Topical corticosteroids, including amcinonide, have not been adequately studied in pregnant women. Animal studies have shown teratogenic effects with systemic. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.